TRAF6 and myelodysplastic syndrome: The same group subsequently reported that an adaptive response to inflammation by MDS HSPCs enhances switching from canonical to noncanonical NF-κB signaling, depending on TLR–TRAF6-mediated activation, and the inhibition of noncanonical NF-κB signaling could prevent the progression of MDS [327].